Salud financiera de hoja de balance de Betta Pharmaceuticals
Salud financiera controles de criterios 3/6
Betta Pharmaceuticals has a total shareholder equity of CN¥5.7B and total debt of CN¥2.3B, which brings its debt-to-equity ratio to 40.6%. Its total assets and total liabilities are CN¥9.4B and CN¥3.6B respectively. Betta Pharmaceuticals's EBIT is CN¥406.6M making its interest coverage ratio 11.2. It has cash and short-term investments of CN¥816.4M.
Información clave
40.6%
Ratio deuda-patrimonio
CN¥2.32b
Deuda
| Ratio de cobertura de intereses | 11.2x |
| Efectivo | CN¥816.38m |
| Patrimonio | CN¥5.73b |
| Total pasivo | CN¥3.63b |
| Activos totales | CN¥9.36b |
Actualizaciones recientes sobre salud financiera
Recent updates
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce
Sep 30
Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 07Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares
Jul 30These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well
Jul 05Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem
Apr 26Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts
Apr 23What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You
Apr 16Análisis de la situación financiera
Pasivos a corto plazo: 300558's short term assets (CN¥1.5B) do not cover its short term liabilities (CN¥1.8B).
Pasivo a largo plazo: 300558's short term assets (CN¥1.5B) do not cover its long term liabilities (CN¥1.9B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 300558's net debt to equity ratio (26.3%) is considered satisfactory.
Reducción de la deuda: 300558's debt to equity ratio has increased from 26.5% to 40.6% over the past 5 years.
Cobertura de la deuda: 300558's debt is well covered by operating cash flow (51%).
Cobertura de intereses: 300558's interest payments on its debt are well covered by EBIT (11.2x coverage).